

Curriculum Vitae



Barbara Casadei, MD, DPhil, FRCP, FMedSci, FESC

Present Position and Address

- *Vice-President for Scientific Affairs* of the European Society of Cardiology
- *British Heart Foundation* Professor of Cardiovascular Medicine, University of Oxford, UK
- Deputy Head of the Division of Cardiovascular Medicine, University of Oxford, UK
- Consultant Cardiologist, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Division of Cardiovascular Medicine, West Wing Level 6, John Radcliffe Hospital, Oxford OX3 9DU, UK

Training and Education

- 1984 MD *cum laude*, University of Pavia, Italy
- 1985 Habilitation to practice medicine (*Distinction*), University of Pavia, Italy
- 1990 Specialist in Cardiology (*Distinction*), University of Pavia, Italy
- 1998 M.R.C.P. London, UK
- 2001 F.R.C.P. London, UK

Post Graduate Degrees

- 1995 DPhil (PhD) in Cardiovascular Medicine, Pembroke College, University of Oxford, UK

European Society of Cardiology Activities

- Nucleus Member & Chair of the *Working Group on Cardiac Cellular Electrophysiology* (2006-08)
- Secretary (2008-2010) and Chair (2012-14) of the *Council for Basic Cardiovascular Science*
- Congress Programme Committee and *Coordinator* of the *ESC Basic Science Track Programme* (2008-12)
- Programme Committee of the *Winter Meeting* of the Heart Failure Association (2005---2014)
- Co-founder and core organiser of the international meetings of the *Council for Basic Cardiovascular Science* of the ESC: *Frontiers in CardioVascular Biology* (FCVB, Berlin 2010, London 2012, Barcelona 2014, Florence 2015).
- Co-chair of “*Best of ESC*” webcast 2011-14
- Associate Editor of *Cardiovascular Research* (2012-)
- Chair of the *ESC Highlights* (2013-14)
- *MEP Heart Group* for Cardiovascular Health Week (Mind your heart – for a heart healthy Europe 2014), European Parliament, Brussels.
- Member of the 2016 *ESC Task Force for the management of atrial fibrillation*
- *Vice-President for Scientific Affairs of the European Society of Cardiology* (2014-16) with a portfolio including:
 - the ESC Taskforce on Research (5-year strategic plan; e.g., including the creation of the ESC scholars, the ESC website portal on research and the research Thinktank),
 - WGs and Councils, e.g., the creation of a taskforce for a new ESC Council on Stroke
 - The “Women in the ESC” Initiative, e.g., the Women Transforming Leadership Programme
 - initiatives to impact on the research regulatory environment in Europe and globally; e.g.,
 - assessing the culture of the working place amongst different National Societies, in partnership with Brandeis University, USA.

Other National and International Scientific Committee Participation

Programme Committee, British Cardiovascular Society (2006-10)

Executive Committee, British Society for Cardiovascular Research (2006-14)

Executive Committee, Association of Physicians of Great Britain and Ireland (2006-8)

Board member, Deutsche Forschungsgemeinschaft (Excellence Cluster) Division Life Sciences, Germany (2006)

Strategic Adviser, EU Commission DG research, Brussels, Belgium (2008)

Scientific Advisory Board (SAB), Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain (2011-)

SAB, National Institute of Cardiovascular and Metabolic Diseases (ICAN), France (2011-14)

SAB, International Research Training Group 1816, German Research Foundation & the King’s College London (2013-)

Chair of the Gordon Research Conference on Cardiac Regulatory Mechanisms, USA (2016)

External advisory board, Department of Cardiovascular Sciences, University of Leuven, Belgium (2016)

Fellowships & Honours

- 1990-91 *Research Fellowship* of the European Society of Cardiology
- 1991 *Syntex Award* for Initiatives in Cardiology, UK
- 1991-94 *Joan and Richard Doll Research Fellowship*, Green College, Oxford
- 1994 *Young Research Workers Prize* of the British Cardiac Society.
- 1995 *Gold Medal* for academic excellence (*Medaglia Teresiana*) of the University of Pavia, Italy.
- 1997 *Fellowship* of the European Society of Cardiology (*FESC*)
- 2004 *The Joan Mott Prize Lecture* of the Physiological Society, UK
- 2007 *The Valsalva Prize Lecture* of the Italian Society of Cardiovascular Research, Italy
- 2013 Fellowship of the UK Academy of Medical Sciences (*FMedSci*)
- 2013 *The William Harvey Lecture* and *Silver Medal* of the European Society of Cardiology
- 2014 *The Thomas Lewis Lecture* and *Silver Medal* of the British Cardiovascular Society
- 2015 *The Carmeliet-Coraboeuf-Weidmann Lecture* of the WG on Cardiac Cellular Electrophysiology.

Major Publications

- Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Guarguagli S, Hill M, Chen ZM, Collins R, **Casadei B**. Perioperative rosuvastatin in cardiac surgery. **New Engl Med J** *In press* 2016
- Reilly SN, Liu X, Carnicer R, Recalde A, Muszkiewicz A, Jayaram R, Carena MC, Stefanini M, Surdo NC, Wijesurenda R, Lomas O, Ratnatunga C, Sayeed R, Krasopoulos G, Rajakumar T, Bueno-Orovio A, Verheule S, Fulga TA, Rodriguez B, Schotten U, **Casadei B**. Atrial-specific upregulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. **Science Transl Med** *In press* 2016
- Wijesurendra RS, **Casadei B**. Atrial fibrillation: effects beyond the atrium? **Cardiovasc Res.** 2015 Mar 1;105(3):238-47 (in "The Best of 2015" <http://eurheartj.oxfordjournals.org/best-of#Cardiovascular-Research>).
- Carnicer R, Hale AB, Suffredini S, Liu X, Reilly S, Zhang MH, Surdo NC, Bendall JK, Crabtree MJ, Lim GB, Alp NJ, Channon KM, **Casadei B**. Cardiomyocyte GTP cyclohydrolase 1 and tetrahydrobiopterin increase NOS1 activity and accelerate myocardial relaxation. **Circulation Research** 2012;111(6):718-27.
- Antoniadou C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Nahar K, Antonopoulos A, Marinou K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Economopoulos G, Koumallos N, Psarros T, Stefanadis C, Channon KM, **Casadei B**. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery: Effects of short-term preoperative statin treatment. **J Am Coll Cardiol.** 2012;59(1):60-70 (published with an Editorial)
- Reilly SN, Jayaram R, Nahar K, Antoniadou C, Verheule S, Channon KM, Alp NJ, Schotten U, **Casadei B**. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. **Circulation** 2011;124(10):1107-17
- Seddon MD, Chowieńczyk P, Brett SE, **Casadei B**, Shah AM. Neuronal nitric oxide synthase (nNOS) regulates basal vascular tone in humans *in vivo*. **Circulation** 2008;117:1991-1996
- Zhang YH, Zhang MH, Sears CE, El-Armouche A, Kranias L, Redwood C, **Casadei B**. A reduced phospholamban phosphorylation contributes to the impaired myocardial relaxation in nNOS knockout mice. **Circulation Research** 2008;102:242-249 (published with an Editorial)
- Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, **Casadei B**. Association of atrial NADPH oxidase activity with the development of atrial fibrillation after cardiac surgery. **J Am Coll Cardiol** 2008;51(1):68-74 (published with an Editorial & reviewed in "Highlights in JACC 2008")
- Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, **Casadei B**. nNOS gene deletion accelerates pathological left ventricular remodeling and functional deterioration after myocardial infarction. **Circulation** 2005;112(24):3729-37 (published with an Editorial).
- Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, **Casadei B**. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. **Circulation Research** 2005;97(7):629-36 (published with an Editorial).

Major Research Interests

- Atrial fibrillation; Perioperative care; Nitric oxide/redox signalling in health and disease.
With my collaborators, I have raised £ 30M in research funds (Gov, Charities and EU FP7 & HZ2020 + ca. £100K of unrestricted research funds from Industry) since 2010.

Statement

I am grateful to my colleagues of the British Cardiovascular Society for proposing my candidature for the Presidency of the ESC. I am a cardiologist who is involved in providing a clinical service, co-chairing an academic department and who also leads a large bench-to-bedside translational research programme; from this position, I believe I can understand and represent the concerns and aspirations of many of the Society's Constituent Bodies.

My personal connection with the ESC: For many years I have thoroughly enjoyed my engagement with the ESC. I started as a ESC Research Fellow in Oxford in 1990 and went on to become Nucleus member and then Chair of the *WG on Cardiac Cellular Electrophysiology*, Secretary and Chair of the *Council for Basic Cardiovascular Science*, founder and core-organiser of the *Frontiers in CardioVascular Biology (FCVB)* meetings, coordinator of the *Basic Science Track* of the ESC meetings, co-chair of the '*Best of ESC*' webcast, and Associate Editor of *Cardiovascular Research*. Since September 2014, I have been a *Vice President (VP)* of the ESC with a wide portfolio including WG & Councils, the 'Women in the ESC' project, Research and Advocacy.

My achievements within the ESC: As a VP, I have drafted the Society's *5-year Strategic Plan for Research*, initiated a number of activities to increase the *engagement of professional women* in the Society, set up a *Taskforce on Stroke*, and *started a campaign* aimed at easing the regulatory burden on clinical research in Europe and promoting safer and more affordable clinical trials.

I am passionate about the need for **inspiring and supporting the career of young clinicians and scientists** in the cardiovascular field and to this end I have initiated or supported a number of initiatives, e.g., the *ESC Summer School*, the "*Scientists of Tomorrow*", the *International Fellowship in Basic & Translational Research*, the *Outstanding Achievement Award*, the *First Contact Initiative Grants*, including a new PhD programme (*the 'ESC Scholars'*) for young researchers across Europe starting next year.

I am also increasingly **concerned about the pressure under which professionals of all ages are working** and the need for documenting these difficulties objectively to be able to impact on them. For this reason I have negotiated the adoption of a validated tool across the ESC membership, i.e., the *C-Change* (for Culture Change) questionnaire (Brandeis University, USA), as a first step to help the ESC and National Societies **develop a strategy that suits the membership's specific needs**.

My vision for the ESC: I strongly endorse the Society's ongoing efforts to achieve **better governance** and a **strong ethical framework**. I believe that, within this framework, the Society's **Constituent Bodies need to be free to pursue their initiatives and aspirations, be supported in their endeavors, and celebrated for their successes**. The future of the ESC depends on it and on the Society's ability to:

- pursue **excellence** and **integrity** and inspire the membership by **setting high standards** for all its activities;
- **facilitate, support** and **help** coordinate the initiatives of the Constituent Bodies;
- **influence** the priorities of health providers, research regulators, and funding agencies to obtain:
 - the best outcomes for patients with cardiovascular disease,
 - the best training for the younger generations,
 - due consideration for **the needs of professionals** engaged in patient care and in clinical and basic research in the cardiovascular field;
- be **efficient** and **accountable** to its membership and increase the **diversity** of its leadership positions;
- engender **work mobility** and the creation of **networks** of excellence for clinical training and research.

International recognition and impact have been generated by the Society's investment in journals, congresses, practice guidelines, training and education. These activities are of great value to the ESC membership and will **continue to be a strong priority**. To these I will add further focus on research (including research training for the younger generation and greater **investment in innovation** and **external collaborations**), and lobbying to ease the research **regulatory environment** and protect our **professional identity**.

I see the ESC Presidency as both a **leadership** position (providing inspiration and innovation from within the Society) and a means of **connecting** and **helping** with the challenges encountered by the ESC membership. I believe the Society's duty is to inspire its members to develop as exemplary leaders, provide a framework for the pursuit of excellence, and support the membership to achieve their objectives and overcome their challenges.

Through my work, I have gained insights into the Society's challenges and enjoyed the friendship of many colleagues with whom I have had the pleasure to work. I am offering my candidature because I feel **I have the energy and the experience** for leading new initiatives within the Society and taking them to fruition. It is a great privilege and a great responsibility to be considered for the position of President Elect of the ESC; it would be an honour and a pleasure to continue to serve the Society in the future.